• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

90.00 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From Merus N.V.
Via GlobeNewswire
News headline image
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
March 06, 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
March 05, 2024
Poster presentation: Monday, April 8, 2024, 9:00 am-12:30 p.m. PT 
From Merus N.V.
Via GlobeNewswire
News headline image
Expert Ratings for Merus ↗
November 28, 2023
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Merus ↗
October 24, 2023
 
Via Benzinga
News headline image
10 Analysts Have This to Say About Merus ↗
September 14, 2023
 
Via Benzinga
News headline image
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
March 04, 2024
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
February 28, 2024
From Merus N.V.
Via GlobeNewswire
News headline image
Merus to Participate in Upcoming Investor Conferences
January 31, 2024
From Merus N.V.
Via GlobeNewswire
News headline image
Where Merus Stands With Analysts ↗
August 10, 2023
 
Via Benzinga
News headline image
Expert Ratings for Merus ↗
July 24, 2023
 
Via Benzinga
News headline image
Analyst Expectations for Merus's Future ↗
June 30, 2023
 
Via Benzinga
News headline image
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
December 02, 2023
MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24 
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
November 26, 2023
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
November 02, 2023
From Merus N.V.
Via GlobeNewswire
News headline image
Merus to Participate in Upcoming Investor Conferences
November 01, 2023
From Merus N.V.
Via GlobeNewswire
News headline image
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
October 23, 2023
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Business Update Conference Call
October 15, 2023
From Merus N.V.
Via GlobeNewswire
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
October 13, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
October 06, 2023
From Merus N.V.
Via GlobeNewswire
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
September 26, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The... 
Via FinancialNewsMedia
News headline image
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst ↗
September 11, 2023
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients  
Via Benzinga
News headline image
Merus to Participate in Upcoming Investor Conferences
August 31, 2023
From Merus N.V.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023 ↗
August 21, 2023
 
Via Benzinga
News headline image
Merus Announces Pricing of Public Offering of Common Shares
August 09, 2023
From Merus N.V.
Via GlobeNewswire
News headline image
Merus N.V. Announces Proposed Public Offering of Common Shares
August 09, 2023
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
August 07, 2023
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
July 28, 2023
From Merus N.V.
Via GlobeNewswire
News headline image
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
July 05, 2023
From Merus N.V.
Via GlobeNewswire
News headline image
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
June 29, 2023
From Merus N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap